Actively Recruiting
Study of TGM-312-SC01 in Healthy Participants and Adults With MASH
Led by Tangram Therapeutics Plc · Updated on 2026-03-27
99
Participants Needed
1
Research Sites
121 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) effects of single ascending doses of TGM-312-SC01 in healthy adults and multiple ascending doses in patients with metabolic dysfunction-associated steatohepatitis (MASH).
CONDITIONS
Official Title
Study of TGM-312-SC01 in Healthy Participants and Adults With MASH
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 70 years who can provide written informed consent
- Medically suitable for study participation based on protocol assessments
- For disease group, clinical features consistent with metabolic dysfunction-associated steatohepatitis as defined in the protocol
You will not qualify if you...
- Clinically significant medical conditions or lab abnormalities that increase risk or interfere with study
- Recent participation in another investigational study
- Use of medications prohibited by the study protocol
- Any other condition making the individual unsuitable for study participation as determined by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Clinical Site 1
London, United Kingdom
Actively Recruiting
Research Team
S
Sponsor Clinical Trials Office
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here